Skip to content

Rapid Uptake Products (RUP)

As part of our support to the Accelerated Access Collaborative, AHSNs are driving adoption of a number of transformative technologies and medicines via the Rapid Uptake Products (RUP) programme.

The Rapid Uptake Products (RUP) programme has been designed to support stronger adoption and spread of proven innovations. It identifies and supports products with NICE approval that support the NHS Long Term Plan’s key clinical priorities, but have lower than expected uptake to date.

The 2020/21 programme builds on the successes of the 2019/20 RUPs programme, with themes selected via an open, staged, selection process.

Pathway Transformation Fund (PTF)

The Pathway Transformation Fund (PTF) is available to help NHS organisations integrate the Rapid Uptake Products into everyday practices. PTF will support projects to overcome barriers to deploying these products which include a severe asthma biologics pathway, measuring fractional exhaled nitric oxide (FeNO) concentration in asthma and a lipid management clinical pathway.

Applications to the PTF should be developed and submitted with the support of your local AHSN RUP lead, and in the West of England – regardless of whether a PTF application is successful – we may also be able to provide project management support to organisations looking to implement 20/21 RUP.

PTF applications must be submitted by 30 April 2021.

Find out more about how the West of England AHSN can support your PTF application.

You can also contact Rachel Gibbons, Senior Project Manager for more information.

The following innovations will be supported through the Rapid Uptake Products (RUP) Programme for 2020/21:

Lipid Management: High Intensity Statins, Ezetimibe and PCSK9 inhibitors

The Rapid Uptake Product (RUP) for lipid management is a novel, NICE-approved clinical pathway. This innovation aims to improve a person’s lipid profile, by reducing cholesterol concentration in blood by treating patients with the right medicine along the evidence-based pathway. The pathway includes three medicines: high intensity statins (HIST), ezetimibe, and PCSK9 inhibitors (continued from 2019/20).

Measuring fractional exhaled nitric oxide (FeNO) concentration in asthma: products NIOX VERO and NObreath

FeNO (fractional exhaled nitric oxide) is a point of care test to measure type two inflammation in airways, which augments and supports the accuracy of asthma diagnosis. The aim of this innovation will be to improve patient care and outcomes by more effective diagnosis of patients suspected of having asthma.

Biologics for treating severe asthma: Reslizumab, Benralizumab, Mepolizumab and Omalizumab

Biological therapies can transform patient lives by reducing long-term side effects of other treatments (e.g. oral corticosteroids (OCS)) and can also reduce the number of exacerbations and life-threatening asthma attacks. The aim of this innovation will be to improve patient care and outcomes by providing a better treatment option for patients with severe asthma.

Tamoxifen for prevention of breast cancer for women at known risk

For women at known risk, Tamoxifen can halve the risk of breast cancer when taken over five years. However, uptake of Tamoxifen is low in clinical practice (roughly 10% in England) due to factors such as access to specialist risk assessment whereby considerations such as family history of reproductive cancers and breast density are reviewed. The aim of this innovation is to improve patient care and outcomes, and ultimately prevent avoidable breast cancer.

Three Rapid Uptake Products from the 2019/20 programme will continue through 2020/21:

  • Placental growth factor (PIGF) based tests to help rule out pre-eclampsia quickly so that pregnant women receive the most appropriate care
  • HeartFlow FFRCT – analysis which creates a 3D model of the coronary arteries to help clinicians to rapidly diagnose patients with suspected coronary artery disease from coronary CT angiography
  • PCSK9 inhibitors – will continue as part of a wider Lipid Management workstream. PCSK9 inhibitors are for the treatment of very high cholesterol, and are used together with a statin-type cholesterol-lowering medicine, or for patients who are unable to take or tolerate a statin.

Innovation and Technology Payment (ITP)

The AAC’s Innovation and Technology (ITP) Programme is delivered in partnership with the AHSNs. It supports NHS England’s commitment to accelerate the adoption and spread of proven and affordable innovations, as set out in the Five Year Forward View and NHS Long Term Plan. Find out more about the ITP programme here.

MedTech Funding Mandate

The NHS Long Term Plan committed to accelerate the uptake of selected innovative medical devices, diagnostics and digital products to patients faster, by developing the MedTech Funding Mandate policy, which is delivered in partnership with AHSNs. Find out more about the MedTech Funding Mandate here.